FDA compounder NDC directory
Browse every current FDA compounder source row, including records that do not contain a usable NDC.
Compounder NDC directory#
Every current compounder source row is browsable, including records whose FDA source did not provide a usable product, package, or lookup NDC. Browse the unified current auxiliary catalog. · Browse the complete captured source and snapshot history.
| Establishment | FEI | Product NDC | Package NDC | Brand | Nonproprietary name | Active ingredients | Period | Normalization | Source date |
|---|---|---|---|---|---|---|---|---|---|
| "QuVa Pharma, Inc.(079937015)" | 70092-269 | 70092-269-37 | Bupivacaine Hydrochloride Anhydrous; Fentanyl Citrate | 156.25 mg/250 mL; 500 ug/250 mL | 2026-1 | valid | 2026-10-06 | ||
| QuVa Pharma, Inc. | 70092-269 | 70092-269-37 | Fent 2 mcg/mlBup 0.0625% PF 250ml NS IVB | Fent 2 mcg/mlBup 0.0625% PF 250ml NS IVB | 156.25 mg/250 mL; 500 ug/250 mL | 2026-1 | valid | 2026-09-18 | |
| "QuVa Pharma, Inc.(079937015)" | 70092-269 | 70092-269-37 | Bupivacaine Hydrochloride Anhydrous; Fentanyl Citrate | 156.25 mg/250 mL; 500 ug/250 mL | 2025-2 | valid | 2026-10-06 | ||
| QuVa Pharma, Inc. | 70092-269 | 70092-269-37 | Fent 2 mcg/mlBup 0.0625% PF 250ml NS IVB | Fent 2 mcg/mlBup 0.0625% PF 250ml NS IVB | 156.25 mg/250 mL; 500 ug/250 mL | 2025-2 | valid | 2026-09-18 | |
| "QuVa Pharma, Inc.(079937015)" | 70092-269 | 70092-269-37 | Bupivacaine Hydrochloride Anhydrous; Fentanyl Citrate | 156.25 mg/250 mL; 500 ug/250 mL | 2025-1 | valid | 2026-10-06 | ||
| QuVa Pharma, Inc. | 70092-269 | 70092-269-37 | Fent 2 mcg/mlBup 0.0625% PF 250ml NS IVB | Fent 2 mcg/mlBup 0.0625% PF 250ml NS IVB | 156.25 mg/250 mL; 500 ug/250 mL | 2025-1 | valid | 2026-09-18 | |
| "QuVa Pharma, Inc.(079937015)" | 70092-269 | 70092-269-37 | Bupivacaine Hydrochloride Anhydrous; Fentanyl Citrate | 156.25 mg/250 mL; 500 ug/250 mL | 2024-2 | valid | 2026-10-06 | ||
| QuVa Pharma, Inc. | 70092-269 | 70092-269-37 | Fent 2 mcg/mlBup 0.0625% PF 250ml NS IVB | Fent 2 mcg/mlBup 0.0625% PF 250ml NS IVB | 156.25 mg/250 mL; 500 ug/250 mL | 2024-2 | valid | 2026-09-18 | |
| QuVa Pharma | 079937015 | 70092-269 | 70092-269-37 | Bupivacaine Hydrochloride Anhydrous; Fentanyl Citrate | 156.25 mg/250 mL; 500 ug/250 mL | 2024-1 | valid | 2026-10-06 | |
| QuVa Pharma | 079937015 | 70092-269 | 70092-269-37 | Bupivacaine Hydrochloride Anhydrous; Fentanyl Citrate | 156.25 mg/250 mL; 500 ug/250 mL | 2023-2 | valid | 2026-10-06 | |
| QuVa Pharma | 079937015 | 70092-269 | 70092-269-37 | Bupivacaine Hydrochloride Anhydrous; Fentanyl Citrate | 156.25 mg/250 mL; 500 ug/250 mL | 2023-1 | valid | 2026-10-06 | |
| QuVa Pharma | 079937015 | 70092-269 | 70092-269-37 | Bupivacaine Hydrochloride Anhydrous; Fentanyl Citrate | 156.25 mg/250 mL; 500 ug/250 mL | 2022-2 | valid | 2026-10-06 | |
| QuVa Pharma | 079937015 | 70092-269 | 70092-269-37 | Bupivacaine Hydrochloride Anhydrous; Fentanyl Citrate | 156.25 mg/250 mL; 500 ug/250 mL | 2022-1 | valid | 2026-10-06 |